Sociedad Argentina de Hematología

ISSN 2250-8309


Declaración de Conflictos de Interés

Cesión de Derechos de Autor

Se solicita enviar ambos formularios a:




Revista Argentina de Hematología


Volumen:    21    # Number : XXIII Congreso Argentino de Hematología

Publication Date :    Noviembre    Year:    2017


Risk-adapted standard treatment of myelodysplastic syndromes

Authors: Hellström-Lindberg E, Tobiasson M, Jädersten M

Abstract: Treatment of MDS has since many years been based mainly on conventional risk scores dividing patients into lower and higher-risk MDS. During recent years the fast development of knowledge about mutational profiles has added significantly to the decisionmaking and has also fostered development of novel targeted drugs in myeloid malignancies. Moreover, the possibilities to guide patients through the hitherto only curative therapeutic option, allogeneic stem cell transplantation, have improved markedly. Hence NGS sequencing is today affecting diagnostics, prognostication, and choice of treatment, as well as the tools for detection of minimal residual disease, and will develop to a natural part of future patient management.

Key words: MDS, treatment, mutations.

Pages :

  Resumen             pdf  

Julián Alvarez 146 - Ciudad Autónoma de Bs As - Argentina
(54-11) 4855-2452 / 2485